HIV mutation literature information.


  Restriction fragment mass polymorphism (RFMP) analysis based on MALDI-TOF mass spectrometry for detecting antiretroviral resistance in HIV-1 infected patients.
 PMID: 23480551       2013       Clinical microbiology and infection
Abstract: The concordance rates between the RFMP and direct sequencing assays for the examined codons were 97% (K65R), 97% (T69Ins/D), 97% (L74VI), 97% (K103N), 96% (V106AM), 97% (Q151M), 97% (Y181C), 97% (M184VI) and 94% (T215YF) in the reverse transcriptase coding region, and 100% (D30N), 100% (M46I), 100% (G48V), 100% (I50V), 100% (I54LS), 99% (V82A), 99% (I84V) and 100% (L90M) in th


  Evaluation of WHO immunologic criteria for treatment failure: implications for detection of virologic failure, evolution of drug resistance and choice of second-line therapy in India.
 PMID: 23735817       2013       Journal of the International AIDS Society
Method: Nucleoside reverse transcriptase inhibitor (NRTI) mutations included in this analysis were as follows: M184V, M184I and M184V/I for lamivudine (3TC) and emtricitabine (FTC) resistance; K65R and K70E, associated with tenofovir (TDF) resistance; thymidine analogue mutations (TAMs) M41L, D67N, K70R, L210W, T215Y, T215F, K219Q, and K219 E, associated with resistance to multiple NRTIs; and multinucleoside mutations, including the


  Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA.
 PMID: 23800377       2013       Retrovirology
Introduction: The excision reaction is facilitated by Excision Enhancement Mutations (EEMs), typically M41L, D67N, K70R, T215Y/F, L210W, and K219E/Q, which are also known as Thymidine Associated Mutations (TAMs) because they were historically linked to resistance to thymidine analogs AZT and d4T.


  Efavirenz stimulates HIV-1 reverse transcriptase RNase H activity by a mechanism involving increased substrate binding and secondary cleavage activity.
 PMID: 23806074       2013       Biochemistry
Method: HIV-1 RT wild type (WT) protein (p66/p51 dimer, NL4-3), (specific activity = 5400 U/mg), patient RT isolate, K101E+G190S+M41L +T215Y, (D10) (specific activity = 7500 U/mg) were expressed and purified in our laboratory as previously described .
Result: The mutant D10 (K101E+G190S+M41L+T215Y) was isolated from a patient who had failed efavirenz treatment .


  Prevalence of drug resistance mutations and HIV type 1 subtypes in an HIV type 1-infected cohort in rural Tanzania.
 PMID: 23806135       2013       AIDS research and human retroviruses
Abstract: In samples from 2009 only K103N (3.3%), M184V, and T215FY (0.8%) were detected.


  Comparisons of Primary HIV-1 Drug Resistance between Recent and Chronic HIV-1 Infection within a Sub-Regional Cohort of Asian Patients.
 PMID: 23826076       2013       PloS one
Abstract: Among those with recent infection, the most common RAMs to nucleoside reverse transcriptase inhibitors (NRTIs) were M184I/V and T215D/E/F/I/S/Y (1.1%), to non-NRTIs was Y181C (1.3%), and to PIs was M46I (1.5%).
Abstract: Of patients with chronic infection, T215D/E/F/I/S/Y (0.8%; NRTI), Y181C (0.5%; non-NRTI), and M46I (0.4%; PI) were the most common RAMs.
Discussio


  Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment Regimens.
 PMID: 23840622       2013       PloS one
Method: Different RT mutations at the same residue were pooled, including the NRTI-resistance mutations D67NG, K70EGQ, L74VI, M184VI, T215YF, K219QE and the NNRTI-resistance mutations K101EH, K103NS, Y188LCH, and G190ASEQ.
Method: Thymidine analogue mutations (TAMs) were defined as M41L, D67NG, K70R, L210W,


  Persistence of HIV-1 transmitted drug resistance mutations.
 PMID: 23904291       2013       The Journal of infectious diseases
Abstract: Most thymidine analogue mutations (TAMs) and T215 revertants (but not T215F/Y) were found to be highly stable, with NNRTI and PI mutations being relatively less persistent.
Result: There was also a rapid transition of T215F and T215Y to one of the T215 revertants, but the revertants themselves were highly stable with a rate of loss of 5 (95% CI, 3-11) mutations per 100 PYFU.
Table: T215Y


  HIV-1 drug-resistance surveillance among treatment-experienced and -naive patients after the implementation of antiretroviral therapy in Ghana.
 PMID: 23977189       2013       PloS one
Abstract: The most prevalent mutation was lamivudine-resistance M184V (n = 12, 38.7%) followed by efavirenz/nevirapine-resistance K103N (n = 9, 29.0%), and zidovudine/stavudine-resistance T215Y/F (n = 6, 19.4%).
Result: As shown in Table 4, the most prevalent drug-resistance mutation among the 31 cases was
Table: T215Y


  Prevalence and mutation patterns of HIV drug resistance from 2010 to 2011 among ART-failure individuals in the Yunnan Province, China.
 PMID: 24009694       2013       PloS one
Result: With the widespread use of AZT and d4T, the resistance mutations associated with these drugs, including K70R, T215F/Y and K219Q/E, were 4.5%, 6.8%, and 5.1%, respectively.
Table: T215Y



Browser Board

 Co-occurred Entities




   Filtrator